A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_ (MissionAD2)

Conditions

Diseases of the Nervous System | Alzheimer's Disease

Phase III

What is the purpose of this trial?

Brief Summary:

The name of this trial is MissionAD2. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to Alzheimer's Disease (AD)/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of elenbecestat (proposed international nonproprietary name [pINN]) (E2609).

http://www.alzheimers.yale.edu


  • Trial with
    Eisai Pharmaceuticals
  • Start Date
    06/30/2018
  • End Date
    08/30/2020
Trial Image

For more information about this study, contact:

Victoria Kominek

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    10/24/2018
  • Study HIC
    #2000022087